Kohei Shigeta

Kohei Shigeta

Auto-generated profile, based on publicly available information

Kohei Shigeta

Department of Surgery, Keio University School of Medicine , Tokyo

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
KSKohei Shigeta
Kohei Shigeta
MDMeenal Datta
Meenal Datta
THTai Hato
Tai Hato
SKShuji Kitahara
Shuji Kitahara
ICIvy X. Chen
Ivy X. Chen
Dan G DudaDan G Duda
Dan G Duda

1 March 2018 in Annals of Surgery
Verified
Journal Article
Closed access
PDF file
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
KOKoji Okabayashi
Koji Okabayashi
HHHirotoshi Hasegawa
Hirotoshi Hasegawa
MTMasashi Tsuruta
Masashi Tsuruta
KSKohei Shigeta
Kohei Shigeta
YKYuko Kitagawa
Yuko Kitagawa
To evaluate the prognostic impact of the systemic inflammation score (SIS) in colorectal cancer (CRC) patients in comparison with a conventional inflammation-based score, the modified Glasgow Prognostic Score (mGPS). The SIS, which is calculated based on the preoperative serum albumin level and lymphocyte-to-monocyte ratio, is a reported prognostic marker in clear-cell renal cell carcinoma. However, the utility of the SIS in CRC remains unclear. The study involved 727 CRC patients who underwent curative resection between September 2005 and December 2011. The prognostic impact of SIS and mGPS was evaluated using survival analyses. The prognostic impact of each score was compared visually by means of time-dependent receiver operating characteristics analysis. The median age of the patients was 67 (interquartile range: 58–75) years. The TNM stage distribution was stage I, 29.8%; stage II, 33.6%; stage III, 30.3%; and stage IV, 6.3%. The median follow-up period was 5.61 years (interquartile range: 4.24–7.06). Multivariate analysis revealed that an increased SIS and mGPS were independent prognostic factors (SIS: P = 0.018; mGPS: P = 0.005, respectively). The time-dependent receiver operating characteristics curve of the SIS was superior to that of the mGPS throughout the observation period. The estimated area under the curve (AUC) of the SIS was significantly higher than that of the mGPS (7-yr survival: SIS 0.673, mGPS 0.605, P = 0.030). The SIS is a novel prognostic factor in CRC patients. Additionally, the SIS is an alternative inflammation-based biomarker, which may improve the prediction of clinical outcomes.

10 February 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
DMDavid G. Millar
David G. Millar
RRRakesh R. Ramjiawan
Rakesh R. Ramjiawan
KKKosuke Kawaguchi
Kosuke Kawaguchi
NGNisha Gupta
Nisha Gupta
JCJiang Chen
Jiang Chen
MCMark Cobbold
Mark Cobbold

1 October 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HLHao Liu
Hao Liu
KNKamila Naxerova
Kamila Naxerova
MPMatthias Pinter
Matthias Pinter
JIJoao Incio
Joao Incio
HLHang Lee
Hang Lee
RJRakesh K. Jain
Rakesh K. Jain
Purpose: Angiotensin system inhibitors (ASI) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients. Experimental Design: We performed an analysis of the records of ASI users and nonuser patients with PDAC seen at Massachusetts General Hospital (Boston, MA) between January 2006 and December 2010. To identify mechanisms of ASIs in PDAC, we performed RNA sequencing (RNA-Seq) of resected primary lesions. Results: A total of 794 consecutive patients were included. In 299 resected patients, ASI users experienced longer overall survival (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P = 0.011) and adjusted multivariate [HR, 0.505; 95% confidence interval (CI), 0.339–0.750; P = 0.001] analyses. Propensity score–adjusted analysis also showed a longer median OS for chronic ASI users. In unresected patients, the beneficial effect of ASIs was significant in patients with locally advanced disease, but not in metastatic patients. RNA-Seq analysis revealed in tumors of ASI users (lisinopril) a normalized extracellular matrix, a reduced expression of genes involved in PDAC progression (e.g., WNT and Notch signaling), and an increased expression of genes linked with the activity of T cells and antigen-presenting cells. Finally, chronic use of ASI was associated with a gene expression signature that is predictive of survival in independent validation cohorts. Conclusions: In patients with nonmetastatic PDAC, chronic ASI use is associated with longer OS independently of chemotherapy. Our RNA-Seq analysis suggests that ASIs reduce the malignant potential of cancer cells and stimulate the immune microenvironment in primary PDAC. Clin Cancer Res; 23(19); 5959–69. ©2017 AACR.

9 June 2016 in British Journal of Cancer
Verified
Journal Article
Open access
TKTakayuki Kondo
Takayuki Kondo
KOKoji Okabayashi
Koji Okabayashi
HHHirotoshi Hasegawa
Hirotoshi Hasegawa
MTMasashi Tsuruta
Masashi Tsuruta
KSKohei Shigeta
Kohei Shigeta
YKYuko Kitagawa
Yuko Kitagawa
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LGLipika Goyal
Lipika Goyal
HZHui Zheng
Hui Zheng
TAThomas A. Abrams
Thomas A. Abrams
RMRebecca Miksad
Rebecca Miksad
ABAndrea J. Bullock
Andrea J. Bullock
AZAndrew X. Zhu
Andrew X. Zhu
PURPOSE: Sorafenib is a standard first-line treatment for advanced HCC. The phase III SHARP trial showed a median time-to-progression(mTTP) of 5.5 months, overall response rate(ORR) of 2%, and median overall survival(mOS) of 10.7 months with sorafenib. FOLFOX4 has shown modest activity in advanced HCC. We evaluated the combination of sorafenib and modified (m)FOLFOX in a single-arm, multicenter phase II study. METHODS: The study included Child-Pugh A patients with advanced HCC and no prior systemic therapies. Patients received sorafenib 400mg BID for 2 weeks, followed by concurrent mFOLFOX (5-FUCI 1200mg/m2/day for 46 hours, leucovorin 200mg/m2 and oxaliplatin 85mg/m2 biweekly). The primary endpoint was mTTP with an alternative hypothesis of 7 months, and secondary endpoints included ORR, mOS, and circulating biomarkers. RESULTS: The study enrolled 40 patients: HCV/Etoh/HBV, 43%/28%/13%; Child-Pugh A5, 70%. Notable grade 3/4 adverse events included AST/ALT elevation(28%/15%), diarrhea(13%), hyperbilirubinemia(10%), hand-foot syndrome(8%), and bleeding(8%). mTTP was 7.7 months[95%CI: 4.4-8.9], ORR 18%, and mOS 15.1 months[7.9-16.9]. Sorafenib+mFOLFOX increased plasma PlGF, VEGF-D, sVEGFR1, IL-12p70 and CAIX and CD4+ and CD8+ effector T lymphocytes and decreased plasma sVEGFR2 and s-c-KIT and Tregs. Shorter TTP was associated with high baseline sVEGFR1. Shorter TTP and OS were associated with increases in Tregs and CD56Dim NK cells after sorafenib alone and plasma sMET after combination treatment (all p<0.05). CONCLUSIONS: Sorafenib+mFOLFOX met the pre-specified endpoint with encouraging efficacy but moderate hepatotoxicity. Thus, this regimen may be effective in select patients with adequate liver reserve. Biomarker evaluations suggested a correlation between TTP and angiogenic biomarkers and circulating Tregs.